Answers are grounded in this paper and cite their sources.
Increasing research suggests the influence of microbial communities within tumors on disease progression, therapeutic responses, and clinical outcomes. The tumor microbiome is a complex niche comprising bacterial, viral, and fungal components that vary across cancer types and influence cancer progression. Tissue-specific microbial signatures suggest niche-specific roles, and their heterogeneity further complicates this landscape, emphasizing the need for high-resolution profiling by multi-omics and imaging approaches to understand the contributions of microbes to tumor behavior and unravel host-microbe interactions. From a therapeutic perspective, modulating the microbiome via probiotics, engineered bacteria/phages, or selective antibiotics is being explored to enhance the efficacy of immunotherapy. Nevertheless, significant challenges persist in our comprehension of microbial causality, overcoming delivery barriers, and developing personalized microbiome interventions. Tumor-associated microbial signatures are being investigated as candidate biomarkers for early detection, prognosis, and treatment response, although clinical validation remains limited.
No takes yet. Share an insight, caveat, or question.
Atoom et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: